# Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer

> **NCT07738172** · PHASE3 · RECRUITING · sponsor: **National Taiwan University Hospital** · enrollment: 154 (estimated)

## Conditions studied

- Lung Neoplasms, Non-Small Cell Lung Cancer

## Interventions

- **PROCEDURE:** Primary Tumor Resection
- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT07738172
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-08
- **Primary completion:** 2031-08-01
- **Final completion:** 2031-08-01
- **Target enrollment:** 154 (ESTIMATED)
- **Last updated:** 2026-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07738172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07738172, "Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07738172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*